Amylyx Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
AMLX$30.21+2.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
Details of our principal properties as of December 31, 2025, are provided below:
| Property Description | Location | SquareFootage | PropertyInterest | Initial LeaseTerm End Date |
|---|---|---|---|---|
| Office space | Cambridge, Massachusetts | 8,850 | Leased | October 2026 |
| Office space | Cambridge, Massachusetts | 15,267 | Leased | December 2030 |
We believe that our facilities are adequate for our current needs and that suitable additional or substitute space would be available if needed.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.